Foundation Medicine, N-of-One Collaborate to Translate Cancer Sequencing Data for Clinical Use | GenomeWeb

NEW YORK (GenomeWeb News) – Cancer care firm N-of-One today announced a deal with Foundation Medicine to translate sequencing data into clinically relevant information.

Under the terms of the agreement, Foundation will identify potential biomarkers using its sequencing and analytic capabilities on patient tumor samples. N-of-One will then use its PrecisionWorks platform to translate data from Foundation to link molecular changes with current information about relevant target therapies and clinical trials that may be used to guide treatment.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.

Some science companies will be taking part in next month's March for Science, Fortune reports.

In Genome Research this week: longitudinal study of Burkholderia cenocepacia isolates from cystic fibrosis patients, long-read assembly approach, and more.

Shale oil companies are turning to DNA sequencing to find spots to drill, Reuters reports.

Apr
13
Sponsored by
SeraCare

In this webinar, Gregory J. Tsongalis of Dartmouth Hitchcock Medical Center will discuss how his lab developed and validated a cancer hotspot assay. 

Apr
27
Sponsored by
SeraCare

This webinar is the third in a four-part series highlighting real-world examples of how some lab directors are bringing validated next-generation sequencing-based tests to the clinic.

May
09
Sponsored by
SeraCare

This webinar is the last in a four-part series highlighting real-world examples of how some lab directors are bringing validated next-generation sequencing-based tests to the clinic.